| No. (%) | No. (%) | P value | |
| Variables | PLR < 162.3 (n = 189) | PLR ≥ 162.3 (n = 75) | |
| Age | |||
| <50 years | 35 (19%) | 18 (24%) | 0.313 |
| >50 years | 154 (81%) | 57 (76%) | |
| Nuclear grade | |||
| 1 - 2 | 126 (67%) | 53 (71%) | 0.846 |
| 3 | 63 (33%) | 22 (29%) | |
| Lymphatic invasion | |||
| Negative | 98 (52%) | 36 (48%) | 0.588 |
| Positive | 91 (48%) | 39 (52%) | |
| Venous invasion | |||
| Negative | 148 (78%) | 47 (63%) | 0.0126 |
| Positive | 41 (22%) | 28 (37%) | |
| Estrogen receptor | |||
| Negative | 33 (17%) | 6 (8%) | 0.0555 |
| Positive | 156 (83%) | 69 (92%) | |
| Progesterone receptor | |||
| Negative | 47 (25%) | 22 (29%) | 0.535 |
| Positive | 142 (75%) | 53 (71%) | |
| HER2 | |||
| Negative | 160 (85%) | 58 (77%) | 0.207 |
| Positive | 29 (15%) | 17 (23%) | |
| Lymph node involvement | |||
| Negative | 139 (72%) | 46 (62%) | 0.054 |
| Positive | 50 (28%) | 29 (38%) | |
| Tumor size | |||
| <20 mm | 94 (50%) | 31 (41%) | 0.223 |
| >20 mm | 95 (50%) | 44 (59%) |